Seattle's Adaptive Biotechnologies has pulled in $105 million from Viking Global Investors to finish off combined Series C and D rounds. The cash infusion will expand the commercial reach of the company's immunosequencing tech to help diagnose and treat cancer, infectious diseases and autoimmune disorders.
Maryland's Diagnostic Biochips is pursuing a $1.5 million round of angel funding to advance development of a microchip brain implant that would be more precise than an MRI in gathering diagnostic data and less invasive than a blood test.
Two of the biggest players in Brazil's diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around.
ResearchDx, one of the few outfits devoted to contract test making, has extended its operation to include the Middle East, a region the company said is home to a growing biotech market.
Starting this January, FierceBiomarkers is merging with its sister publication, FierceDiagnostics. FierceDiagnostics will retain its name and brand, but coverage will expand to include the use of biomarkers as they relate to the broader diagnostics industry.
Hologic now has a fresh CEO and two added board members, thanks to the machinations of activist investor Carl Icahn. But the new leader of the Massachusetts company known for women-focused diagnostic medical imaging and surgical products insists growth is a much bigger priority over a sale, at least for now.
Researchers have come up with an affordable, quick and accurate way to diagnose brain cancer in a fraction of the time that current technology allows. The early results are promising enough that they've patented their new approach.
Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.
Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.
Considering the number of milestones Oxford Immunotec Global has already achieved, the maker of a next-generation tuberculosis diagnostic test could very easily hit the high end of its targeted $13-$15 IPO price range.